Understanding the impact of GLP-1 treatments on the liver is crucial, as perturbations to both cellular lipid and very-low-density lipoprotein (VLDL) metabolism are associated with development of hepatic insulin resistance, obesity and diabetes. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.